[关键词]
[摘要]
目的:探讨青光眼模型经芍药二酮干预对视神经损伤及视网膜小胶质细胞M1/M2极化的影响。方法:选取40只健康SPF级雌雄各半SD大鼠,选其中10只作为空白对照组,剩余30只用于建立青光眼模型。最终造模成功28只(另2只造模失败),将造模成功的28只大鼠采用简单随机数字表法分为模型组、芍药二酮低剂量组、芍药二酮中剂量组、芍药二酮高剂量组,每组7只,检测并对比各组眼压、视网膜形态结构、视网膜厚度、RGC数量、RGC凋亡率、视网膜小胶质细胞M1/M2极化、炎症因子、氧化应激、线粒体受损情况、内质网应激途径。结果:给药前~给药4周后,与空白对照组相比,模型组、芍药二酮低剂量组、芍药二酮中剂量组、芍药二酮高剂量组眼压升高;与空白对照组相比,模型组、芍药二酮低剂量组、芍药二酮中剂量组眼压、RGC凋亡率、M1型小胶质细胞数量、IL-1β、TNF-α、IL-18、MDA、CHOP、GRP78升高,RGC数量、视网膜厚度、M2型小胶质细胞数量、SOD、GSH-PX、Cytc/a、P/O下降;与模型组相比,芍药二酮低剂量组、中剂量组、高剂量组RGC凋亡率、眼压、M1型小胶质细胞数量、IL-1β、TNF-α、IL-18、MDA、CHOP、GRP78逐渐降低,RGC数量、视网膜厚度、M2型小胶质细胞数量、SOD、GSH-PX、Cytc/a、P/O逐渐升高,差异具有统计学意义(P<0.05)。结论:芍药二酮可剂量依赖性降低青光眼大鼠眼压,改善视网膜结构,减少RGC凋亡,该药通过抑制小胶质细胞M1极化、促进M2极化以减轻炎症反应,提升抗氧化能力,并抑制内质网应激、改善线粒体损伤,进而保护受损视神经。本研究采用灌胃给药方式,与临床常用滴眼液局部给药存在区别,仍有待进一步探究该药物眼部局部给药的作用效果。
[Key word]
[Abstract]
Objective:? To investigate the effects of paeonidone intervention on optic nerve injury and M1/M2 polarization of retinal microglia in a glaucoma model.Methods:? Forty healthy SPF-grade Sprague-Dawley (SD) rats (half male and half female) were selected. Ten rats were assigned as the blank control group, and the remaining 30 were used to establish the glaucoma model. Ultimately, 28 rats were successfully modeled (2 failed), and these 28 rats were randomly divided into four groups (n = 7 per group) using a simple random number table: model group, low-dose paeonidone group, medium-dose paeonidone group, and high-dose paeonidone group. Intraocular pressure (IOP), retinal morphology, retinal thickness, retinal ganglion cell (RGC) count, RGC apoptosis rate, M1/M2 polarization of retinal microglia, inflammatory cytokines, oxidative stress markers, mitochondrial damage, and endoplasmic reticulum (ER) stress pathways were detected and compared among the groups.Results:? From pre-administration to 4 weeks post-administration, IOP was significantly higher in the model group and all paeonidone-treated groups compared with the blank control group. Compared with the blank control group, the model group and the low- and medium-dose paeonidone groups showed significantly increased IOP, RGC apoptosis rate, M1 microglia count, levels of IL-1β, TNF-α, and IL-18, malondialdehyde (MDA), and CHOP and GRP78 expression, along with significantly decreased RGC count, retinal thickness, M2 microglia count, superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), Cytc/a, and P/O ratio (all P < 0.05). Compared with the model group, the low-, medium-, and high-dose paeonidone groups showed gradual decreases in RGC apoptosis rate, IOP, M1 microglia count, IL-1β, TNF-α, IL-18, MDA, CHOP, and GRP78, and gradual increases in RGC count, retinal thickness, M2 microglia count, SOD, GSH-PX, Cytc/a, and P/O ratio, with statistically significant differences (P < 0.05).Conclusion:? paeonidone can dose-dependently reduce IOP in glaucomatous rats, improve retinal structure, and decrease RGC apoptosis. The drug exerts neuroprotective effects on the injured optic nerve by inhibiting M1 polarization and promoting M2 polarization of microglia, thereby alleviating inflammation, enhancing antioxidant capacity, and suppressing ER stress while ameliorating mitochondrial damage. It should be noted that this study used intragastric administration, which differs from the topical eye drop administration commonly used in clinical practice; further investigation is needed to evaluate the efficacy of topical ocular administration of this drug.
[中图分类号]
[基金项目]